AgingResearch.NewsJoin free

ST6GAL1

Gene

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

A gene’s or a process’s line counts the gene with the processes named after it, as NLRP3 with the NLRP3 inflammasome, and the trials of drugs aimed at it.

  • 1 lab in 1 country
  • Funders: National Institute of Diabetes and Digestive and Kidney Diseases and 2 more
  • Cells1

Effects

1

Cell-surface retention of TRPV5

is required forin cells1

1 study

  1. ST6GAL1 is required for cell-surface retention of TRPV5 in cells.

    “Knockdown of beta-galactoside alpha2,6-sialyltransferase (ST6Gal-1) by RNA interference, but not other sialyltransferases, in a human cell line prevents the regulation by Klotho.”

    CellsKlotho regulation of TRPV5

    Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1

    Proceedings of the National Academy of Sciences of the United States of America7 Jul 2008

Latest

Related